IFN mimetic as a therapeutic for lethal vaccinia virus infection: Possible effects on innate and adaptive immune responses

Journal of Immunology

Volumn 178, Issue 7, 2007, Pages 4576-4583

  Ahmed, Chulbul M ^a   Martin, James P ^a   Johnson, Howard M ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON DERIVATIVE; GAMMA INTERFERON[95-106]; GAMMA INTERFERON[95-125]; GAMMA INTERFERON[95-132]; PROTEIN B8R; UNCLASSIFIED DRUG; VIRULENCE FACTOR; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; HUMORAL IMMUNITY; IMMUNITY; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA; VACCINIA VIRUS;

EID: 33947638071     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.7.4576     Document Type: Article

References (33)

1. Samuel, C. E. 2001. Antiviral actions of interferons. Clin. Microbiol. Rev. 14: 778-809.
2. Stark, G. R., I. M. Kerr, B. R. Williams, R. H. Silverman, and R. D. Schreiber. 1998. How cells respond to interferons. Annu. Rev. Biochem. 67: 227-264.
3. Pestka, S., C. D. Krause, and M. R. Walter. 2004. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202: 8-32.
4. Pestka, S., S. V. Kotenko, G. Muthukumaran, L. S. Izotova, and G. Garotta. 1997. The interferon γ receptor: a paradigm for the multichain cytokine receptor. Cytokine Growth Factor Rev. 3: 189-206.
5. Brivanlou, A. H., and J. E. Darnell, Jr. 2002. Signal transduction and the control of gene expression. Science 295: 813-818.
6. Johnson, H. M., P. S. Subramaniam, S. Olsnes, andD. A. Jans. 2004. Trafficking and signaling pathways of nuclear localizing protein ligands and their receptors. BioEssays 26: 993-1004.
7. McFadden, G. 2005. Poxvirus tropism. Nat. Rev. Microbiol. 3: 201-213.
8. DiGiulio, D. B., and P. B. Eckburg. 2004. Human monkeypox: an emerging zoonosis. Lancet Infect. Dis. 4: 15-25.
9. Alcami, A., and G. L. Smith. 2002. The vaccinia virus soluble interferon γ receptor is a homodimer. J. Gen. Virol. 83: 545-549.
10. Szente, B. E., J. M. Soos, and H. M. Johnson. 1994. The C-terminus of IFN γ is sufficient for intracellular function. Biochem. Biophys. Res. Commun. 203: 1645-1654.
11. Subramaniam, P. S., M. M. Green, J. Larkin, B. A. Torres, and H. M. Johnson. 2001. Nuclear translocation of IFNγ is an intrinsic requirement for its biologic activity and can be driven by a heterologous nuclear localization sequence. J. Interferon Cytokine Res. 21: 951-959.
12. Ahmed, C. M. I., M. A. Burkhart, P. S. Subramaniam, M. G. Mujtaba, and H. M. Johnson. 2005. Peptide mimetics of γ interferon possess antiviral properties against vaccinia virus and other viruses in the presence of poxvirus B8R protein. J. Virol. 79: 5632-5639.
13. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J., A. Smith, and K. Struhl, eds. 2002. Short Protocols in Molecular Biology. Wiley, New York, pp. 16-65.
14. 3H-thymidine incorporation assay. J. Immunol. Methods 170: 211-214.
15. Moss, B., and J. L. Shisler. 2001. Immunology 101 at poxvirus U: immune evasion genes. Semin. Immunol. 13: 59-66.
16. Yang, H., K. Sung-Kwon, M. Kim, P. A. Reche, T. J. Morehead, I. K. Damon, R. M. Welsh, and E. L. Reinherz. 2005. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 115: 379-387.
17. Reeves, P. M., B. Bommarius, S. Lebeis, S. McNulty, J. Christensen, A. Swimm, A. Chahroudi, R. Chavan, M. B. Feinberg, D. Veach, et al. 2005. Disabling poxvirus pathogenesis by inhibition of abl-family tyrosine kinases. Nat. Med. 11: 731-739.
18. Szente, B. E., I. J. Weiner, M. J. Jablonsky, N. R. Krishna, B. A. Torres, and H. M. Johnson. 1996. Structural requirements for agonist activity of a murine interferon γ peptide. J. Interferon Cytokine Res. 16: 813-817.
19. Alcami, A., and G. L. Smith. 1995. Vaccinia, cowpox, and camelpox viruses encode soluble γ interferon receptors with novel broad species specificity. J. Virol. 69: 4633-4639.
20. Symons, J. A., Tscharke, D. C., Price, N., and G. L. Smith. 2002. A study of the vaccinia virus interferon γ receptor and its contribution to the virus virulence. J. Gen. Virol. 83: 1953-1964.
21. Ahmed, C. M. I., M. A. Burkhart, M. G. Mujtaba, P. S. Subramaniam, and H. M. Johnson. 2003. The role of IFN γ nuclear localization sequence in intracellular function. J. Cell Sci. 116: 3089-3098.
22. Ahmed, C. M. I., and H. M. Johnson. 2006. IFN-γ and its receptor subunit IFNGR1 are recruited to the IFN-γ-activated sequence element at the promoter site of IFNγ-activated genes: evidence of transactivational activity in IFNGR1. J. Immunol. 177: 315-321.
23. Subramaniam, P. S., M. G. Mujtaba, M. R. Paddy, and H. M. Johnson. 1999. The carboxyl terminal of interferon γ contains a functional polybasic nuclear localization sequence. J. Biol. Chem. 274: 403-407.
24. Subramaniam, P. S., J. Larkin, M. G. Mujtaba, M. R. Walter, and H. M. Johnson. 2000. The COOH-terminal nuclear localization sequence of interferon γ regulates STAT1 α nuclear translocation at an intracellular site. J. Cell Sci. 113:2771-2781.
25. Subramaniam, P. S., L. O. Flowers, S. M Haider, and H. M. Johnson. 2004. Signal transduction mechanism of a peptide mimetic of interferon γ. Biochemistry 43: 5445-5454.
26. Subramaniam, P. S., B. A. Torres, and H. M. Johnson. 2001. So many ligands, so few transcription factors. Cytokine 15: 175-187.
27. Mujtaba, M. G., C. B. Patel, R. A. Patel, L. O. Flowers, M. A. Burkhart, L. W. Waiboci, J. Martin, M. I. Haider, C. M. Ahmed, and H. M. Johnson. 2006. The γ interferon mimetic peptide IFN-γ(95-133) prevents encephalomyocarditis virus infection both in tissue culture and in mice. Clin. Vaccine Immunol. 13: 944-952.
28. Verardi, P., L. A. Jones, F. H. Aziz, S. Ahmad, and T. D. Yilma. 2001. Vaccinia virus vectors with an inactivated γ interferon receptor homolog gene (B8R) are attenuated in vivo without concomitant reduction in immunogenicity. J. Virol. 75: 11-18.
29. Gutfreund, H. 1995. Kinetics for the Life Science. Cambridge University Press, Cambridge, U.K., pp. 45-102.
30. Jackson, R. J., A. J. Ramsay, C. D. Christensen, S. Beaton, D. F. Hall, and I. A. Ramshaw. 2001. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 75: 1205-1210.
31. Stittelaar, K. J., J. Neyts, L. Naesens, G. van Amerongen, R. F. van Lavieren, A. Holy, E. De Clerq, H. G. M. Niesters, E. Fries, C. Maas, et al. 2006. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 439: 745-748.
32. Stanford, M. M., and G. McFadden. 2005. The 'supervirus'? Lessons from IL-4-expressing poxviruses. Trends Immunol. 26: 339-345.
33. Kim, M., H. Yang, S. K. Kim, P. A. Reche, R. S. Tirabassi, R. E. Hussey, Y. Chishti, J. G. Rheinwald, T. J. Morehead, T. Zech, et al. 2004. Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies. J. Biol. Chem. 279: 25838-25848.